Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.6% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06372470Completed

Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment

Role: lead

NCT06745726Withdrawn

OptiZ: Real World Evidence Study

Role: lead

NCT07216651Completed

WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

Role: lead

NCT05093426Completed

PERSONAL - Sleep In Breast Cancer

Role: lead

All 4 trials loaded